Gut hormones and the brain

Journal of Diabetes

Volumn 2, Issue 3, 2010, Pages 138-145

  Zhang, Yifei ^a   Ning, Guang ^a   Handelsman, Yehuda ^b   Bloomgarden, Zachary T ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Metabolic Institute of America   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

bile acids; farnesoid X receptor; gut hormones; incretin; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; AMYLIN; BILE ACID; CHOLECYSTOKININ; COLESEVELAM; COLESTILAN; COLESTIPOL; COLESTYRAMINE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; G PROTEIN COUPLED RECEPTOR; GASTROINTESTINAL HORMONE; GHRELIN; INCRETIN; LEPTIN; LIRAGLUTIDE; METFORMIN; PRAMLINTIDE; PROTEIN KINASE C; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ABDOMINAL PAIN; BILE ACID METABOLISM; BLOATING; BRAIN; CLINICAL PRACTICE; CONSTIPATION; FLATULENCE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

BILE ACIDS AND SALTS; BRAIN; GASTROINTESTINAL HORMONES; GHRELIN; GLUCOSE; HOMEOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA; INCRETINS; LEPTIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SATIETY RESPONSE;

EID: 77955808114     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2009.00056.x     Document Type: Review

References (48)

1. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995 75 : 473 86.
2. Brüning JC, Gautam D, Burks DJ et al. Role of brain insulin recetpro in control of body weight and reproduction. Science. 2000 289 : 2122 5.
3. Korner J, Leibel RL. To eat or not to eat - How the gut talks to the brain. N Engl J Med. 2003 349 : 926 8.
4. Kuipers F, Stroeve JHM, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr Opin Lipidol. 2007 18 : 289 97.
5. Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal. 2008 20 : 2180 97.
6. Nomiyama T, Bruemmer D. Liver x receptors as therapeutic targets in metabolism and atherosclerosis. Curr Atheroscler Rep. 2008 10 : 88 95.
7. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009 89 : 147 91.
8. Pellicciari R, Fiorucci S, Camaioni E et al. 6-Ethyl-Chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002 45 : 3569 72.
9. Rizzo G, Disante M, Mencarelli A et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol. 2006 70 : 1164 73.
10. Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009 296 : H272 81.
11. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008 7 : 678 93.
12. Duran-Sandoval D, Cariou B, Percevault F et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem. 2005 280 : 29971 9.
13. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005 25 : 2020 30.
14. Kawamata Y, Fujii R, Hosoya M et al. A g protein-coupled receptor responsive to bile acids. J Biol Chem. 2003 278 : 9435 40.
15. Thomas C, Auwerx J, Schoonjans K. Bile Acids and the Membrane Bile Acid Receptor TGR5 - Connecting Nutrition and Metabolism. Thyroid. 2008 18 : 167 74.
16. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm. 2008 5 : 42 8.
17. Kharitonenkov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs. 2008 22 : 37 44.
18. Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005 115 : 1627 35.
19. Moore DD. Physiolgy. Sister act. Science. 2007 316 : 1436 8.
20. Pandak WM, Ren S, Marques D et al. Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes. J Biol Chem. 2002 277 : 48158 64.
21. Khan SA, Heuvel JPV. Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). J Nutr Biochem. 2003 14 : 554 67.
22. Dent P, Fang Y, Gupta S et al. Conjugated bile acids promote ERK12 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. Hepatology. 2005 42 : 1291 9.
23. Ren S, Li X, Rodriguez-Agudo D, Gil G, Hylemon P, Pandak WM. sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes. Biochem Biophys Res Commun. 2007 360 : 802 8.
24. Ranganath LR. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J Clin Pathol. 2008 61 : 401 9.
25. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005 307 : 1909 14.
26. Strader AD, Wood SC. Gastrointestinal hormones and food intake. Gastroenterology. 2005 128 : 175 91.
27. Riedy CA, Chavez M, Figlewicz DP, Woods SC. Central insulin enhances sensitivity to cholecystokinin. Physiol Behav. 1995 58 : 755 60.
28. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes. 2006 55 : 3387 93.
29. de HeerJ, hoy MK, Holst JJ GLP-1, but not GIP, inhibits glucagon secretion via somatostatin in the perfused rat pancreas. Abstract 164. Program and abstracts of the European Association for the study of Diabetes. 41st Annual Meeting, 12-15 September 2005, Athens, Greece.
30. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G. Amylin: history and overview. Diabet Med. 1997 14 (Suppl 2 S9 13.
31. Sobhani I, Bado A, Vissuzaine C et al. Leptin secretion and leptin receptor in the human stomach. Gut. 2000 47 : 178 83.
32. Woods SC, Lotter EC, McKay LD, Porte D Jr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature. 1979 282 : 503 5.
33. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001 50 : 1714 9.
34. Wren AM, Small CJ, Abbott CR et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001 50 : 2540 7.
35. Porte D Jr., Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW. Obesity, diabetes and the central nervous system. Diabetologia. 1998 41 : 863 81.
36. Schwartz MW, Woods SC, Porte D Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000 404 : 661 71.
37. Campfield LA, Smith FJ, Burn P. Strategies and potential molecular gargets for obesity treatment. Science. 1998 280 : 1383 7.
38. Hagan MM. Peptide YY: a key mediator of orexigenic behavior. Peptides. 2002 23 : 377 82.
39. Hagan MM, Moss DE. Suppression of peptide YY-induced hyperphagia by terbutaline. Pharmacol Biochem Behav. 1993 46 : 679 81.
40. Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrinemetabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002 110 : 1093 103.
41. Hallschmid M, Benedict C, Schultes B, Fehm H, Born J, Kern W. Intranasal insulin reduces body fat in men but not in women. Diabetes. 2004 53 : 3024 9.
42. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther. 2007 14 : 567 80.
43. Suzuki T, Oba K, Igari Y et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like peptide-1 (7-36) levels inpatients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch. 2007 74 : 338 43.
44. Levy P. Bile acid sequestrants as a therapeutic option for glucose lowering in type 2 diabetes mellitus. Endocr Pract. 2008 14 : 644 7.
45. Staels B, Kuipers F. Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus. Drugs. 2007 67 : 1383 92.
46. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 101 : 515 20.
47. Rodbard HW, Blonde L, Braithwaite SS et al. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007 13 (Suppl 1 1 68.
48. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003 26 : 2929 40.